Bifogade filer
Presentation of Spago Nanomedical's clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis
Kurs
-2,01%
Likviditet
0,16 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | N/A | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2025-05-14 | N/A | Årsstämma |
| 2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-11 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2024-06-10 | - | Årsstämma |
| 2024-05-02 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-07 | - | Bokslutskommuniké 2023 |
| 2023-11-03 | - | Kvartalsrapport 2023-Q3 |
| 2023-10-31 | - | Extra Bolagsstämma 2023 |
| 2023-07-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2023-05-10 | - | Årsstämma |
| 2023-05-09 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-11-08 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2022-05-18 | - | Årsstämma |
| 2022-04-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-02 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-02 | - | Bokslutskommuniké 2020 |
| 2021-01-15 | - | Extra Bolagsstämma 2021 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-24 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-29 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Extra Bolagsstämma 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-05-09 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-01-30 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-11-08 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-22 | - | Extra Bolagsstämma 2017 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2017-05-17 | - | Årsstämma |
| 2017-04-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-14 | - | Bokslutskommuniké 2016 |
| 2016-11-08 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2016-05-11 | - | Årsstämma |
| 2016-04-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-12 | - | Bokslutskommuniké 2015 |
| 2015-11-12 | - | Extra Bolagsstämma 2015 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-27 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-06 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2015-05-05 | - | Årsstämma |
| 2015-04-29 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-27 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-30 | - | X-dag ordinarie utdelning SPAGO 0.00 SEK |
| 2014-04-29 | - | Årsstämma |
| 2014-04-29 | - | Extra Bolagsstämma 2014 |
| 2014-04-29 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-21 | - | Bokslutskommuniké 2013 |
| 2013-10-29 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-29 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-25 | - | Årsstämma |
| 2013-02-22 | - | Bokslutskommuniké 2012 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Spago Nanomedical AB (publ) announces today that principal investigator Dr Ligita Jokubkiene is participating in the 15th World Congress on Endometriosis scientific conference where she will present observations from the ongoing phase IIa clinical study SPAGOPIX-02 evaluating the contrast agent SN132D in endometriosis.
In the presentation, entitled "Performance of the novel intravenous contrast agent SN132D in combination with magnetic resonance imaging in detecting deep endometriosis lesions: initial results of a Phase IIa clinical trial SPAGOPIX-02", it is stated that endometriosis is an undertreated disease in great need of improved diagnostic methods. Observations from patients examined so far may indicate contrast enhancement of deep lesions (deep endometriosis) and support further study recruitment.
SPAGOPIX-02 is an open-label, proof-of-concept study to evaluate the safety and MRI-enhancing properties of SN132D in patients with suspected endometriosis. The recruitment of remaining patients in the study continues and preliminary results are expected as planned around mid-year.
The contrast agent SN132D has previously been evaluated in the phase I clinical study SPAGOPIX-01 in patients with confirmed breast cancer. Initial results from the study show that SN132D is well tolerated and provides clear contrast in MRI images of solid tumors in the breast, as well as in the pancreas and liver. Final report of the study is under preparation.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.